Roles of PPARs in NAFLD: Potential therapeutic targets

Steatohepatitis: A tale of two “hits”?

Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327

Cloning of adiponectin receptors that mediate antidiabetic metabolic effects

Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., Sugiyama, T., Miyagishi, M., Hara, K., Tsunoda, M., et al. (2003) · Nature · doi:10.1038/nature01705 · Cited by 3,176

Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis

Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

Berg, A. H., Combs, T. P., Du, X., Brownlee, M., & Scherer, P. E. (2001) · Nature Medicine · doi:10.1038/90992 · Cited by 2,526

Macrophage-specific PPARγ controls alternative activation and improves insulin resistance

Odegaard, J. I., Ricardo-Gonzalez, R. R., Goforth, M. H., Morel, C. R., Subramanian, V., Mukundan, L., Eagle, A. R., Vats, D., Brombacher, F., Ferrante, A. W., et al. (2007) · Nature · doi:10.1038/nature05894 · Cited by 2,107

Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease

Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827

Regulation of hepatic fatty acid oxidation and ketone body production

McGarry, J. D., & Foster, D. W. (1980) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.49.070180.002143 · Cited by 1,460

Adipose tissue as a buffer for daily lipid flux

Frayn, K. (2002) · Diabetologia · doi:10.1007/s00125-002-0873-y · Cited by 752

Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss

Dixon, J. B., Bhathal, P. S., Hughes, N. R., & O'Brien, P. E. (2004) · Hepatology · doi:10.1002/hep.20251 · Cited by 727

Adipocyte-Derived Th2 Cytokines and Myeloid PPARδ Regulate Macrophage Polarization and Insulin Sensitivity

Kang, K., Reilly, S. M., Karabacak, V., Gangl, M. R., Fitzgerald, K., Hatano, B., & Lee, C.-H. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.04.002 · Cited by 699

Metformin in non-alcoholic steatohepatitis.

Marchesini, G., Bianchi, G., Tomassetti, S., Zoli, M., & Melchionda, N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06042-1 · Cited by 682

Metformin reverses fatty liver disease in obese, leptin-deficient mice.

Lin, H. Z., Yang, S. Q., Chuckaree, C., Kuhajda, F., Ronnet, G., & Diehl, A. M. (2000) · Nature Medicine · doi:10.1038/79697 · Cited by 673

Peroxisome proliferator-activated receptors and hepatic stellate cell activation

Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006577200 · Cited by 473

Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD)

Bellentani, S., & Marino, M. (2009) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31820-4 · Cited by 322

Peroxisome Proliferator-activated Receptor γ Induces a Phenotypic Switch from Activated to Quiescent Hepatic Stellate Cells

Hazra, S., Xiong, S., Wang, J., Rippe, R. A., Krishna, V., Chatterjee, K., & Tsukamoto, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310284200 · Cited by 320

Safety issues and prospects for future generations of PPAR modulators

RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309

Hepatic Steatosis: A Mediator of the Metabolic Syndrome. Lessons From Animal Models

den Boer, M., Voshol, P. J., Kuipers, F., Havekes, L. M., & Romijn, J. A. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000116217.57583.6e · Cited by 260

Global Suppression of IL-6-induced Acute Phase Response Gene Expression after Chronic in Vivo Treatment with the Peroxisome Proliferator-activated Receptor-α Activator Fenofibrate

Gervois, P., Kleemann, R., Pilon, A., Percevault, F., Koenig, W., Staels, B., & Kooistra, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400346200 · Cited by 212

Peroxisome proliferator-activated receptor γ transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells

Galli, A., Crabb, D., Price, D., Ceni, E., Salzano, R., Surrenti, C., & Casini, A. (2000) · Hepatology · doi:10.1002/hep.510310117 · Cited by 197

PPARγ agonists prevent TGFβ1/Smad3-signaling in human hepatic stellate cells

Zhao, C., Chen, W., Yang, L., Chen, L., Stimpson, S. A., & Diehl, A. M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.09.069 · Cited by 139

Ligand Activation of Peroxisome Proliferator–Activated Receptor β/δ (PPARβ/δ) Attenuates Carbon Tetrachloride Hepatotoxicity by Downregulating Proinflammatory Gene Expression

Shan, W., Palkar, P. S., Murray, I. A., McDevitt, E. I., Kennett, M. J., Kang, B. H., Isom, H. C., Perdew, G. H., Gonzalez, F. J., & Peters, J. M. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn142 · Cited by 97

PPARβ regulates vitamin A metabolism-related gene expression in hepatic stellate cells undergoing activation

Hellemans, K., Rombouts, K., Quartier, E., Dittié, A. S., Knorr, A., Michalik, L., Rogiers, V., Schuit, F., Wahli, W., & Geerts, A. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m200376-jlr200 · Cited by 64

Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease

Pawlak, M., Lefebvre, P., & Staels, B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.039 · Cited by 1,578

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: Hepatology

Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414

Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors

Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316

Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)

Qiu, Y.-Y., Zhang, J., Zeng, F.-Y., & Zhu, Y. Z. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106786 · Cited by 271

Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists

Fruchart, J.-C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-82 · Cited by 189